COMMUNIQUÉS West-GlobeNewswire

Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow
05/11/2018
ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
INSYS Therapeutics Reports Third Quarter 2018 Results
05/11/2018
Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: [...]
Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
05/11/2018
DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets
05/11/2018
Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and [...]
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05/11/2018
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- [...]
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
05/11/2018
WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and [...]
Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results
05/11/2018
- Biologics License Application (BLA) submission on track for Q1 2019 - - Robust manufacturing package for BLA submission to include positive results from pharmacokinetic comparability study - - Conference call today at [...]
Iterum Therapeutics plc to Participate in Investor Conferences in November and December
05/11/2018
DUBLIN, Ireland and CHICAGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today [...]
Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05/11/2018
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and CXCL12+ cohorts in Phase [...]
Rubius Therapeutics to Announce Third Quarter 2018 Financial Results
05/11/2018
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, plans to report third quarter 2018 [...]
Akcea Reports Financial Results and Highlights for Third Quarter 2018
05/11/2018
TEGSEDI TM (inotersen) Approved in United States, European Union & Canada $320 million to fund the company through key milestones Conference Call Webcast Monday, November 5, 4:30 p.m. ET at www.akceatx.com BOSTON, [...]
Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
05/11/2018
NOVATO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases [...]
Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights
05/11/2018
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter [...]
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
05/11/2018
NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing [...]
MRI Interventions, Inc. to Announce Third Quarter 2018 Results on November 12
05/11/2018
IRVINE, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) announced that it will release financial results for its 2018 third quarter, which ended September 30, 2018, on Monday, November 12 [...]
Evolus Reports Third Quarter 2018 Financial Results
05/11/2018
- Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET - IRVINE, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. ( [...]
Neos Therapeutics Announces Proposed Offering of Common Stock
05/11/2018
DALLAS and FORT WORTH, Texas, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative [...]
Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
05/11/2018
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended [...]
REVA Medical Reports Third Quarter 2018 Financial Results
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update [...]

Pages